Writing
Writing
Notes on compounding regulation, credentialing standards, and peptide medicine.
01 Articles
What the July 2026 PCAC Votes Did and Did Not Do
The July 2026 votes of the FDA's Pharmacy Compounding Advisory Committee were advisory recommendations, not final agency action. Formal notice-and-comment rulemaking must follow before any change carries legal effect.
Why Peptide Medicine Needs a Standards Layer
Peptide medicine has grown faster than the structures meant to keep it accountable. This piece describes the gap between what is legal and what is verifiable.
What Clinicians Get Wrong About Peptide Sourcing
A supplier is not a standard. This piece explains the difference and why it matters when working with providers.
02 At PepMD
PCAC Votes Six of Seven Peptides Onto the 503A List
What the committee actually voted on, and why a recommendation is not yet a rule.
Import Alert 66-80 and the Peptide API Supply Chain
How green list status shapes which active ingredients reach American compounders.
A Secret Shopper Study of Online GLP-1 Prescribing Oversight
What the findings show about clinical review in direct to consumer prescribing.
State Compounding Standards Under USP 795 and 797
Ohio and Texas illustrate how unevenly state boards adopt the same chapters.
FDA Proposes Excluding GLP-1s From the 503B Bulks List
The proposal, the comment window, and what outsourcing facilities should read closely.
